CURE Pharmaceutical Holding Corp. (CURR)
Stock Price:
$1.14 USD
-0.06 (-5.00%)
Updated Oct 26, 2020 1:29 PM EDT - Market open
Key Info
| Market Cap |
58.20M |
| Revenue (ttm) |
990,000 |
| Net Income (ttm) |
-10.08M |
| Shares Out |
51.06M |
| EPS (ttm) |
-0.26 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 26, 2020 |
| Last Price |
$1.14 |
| Previous Close |
$1.20 |
| Change ($) |
-0.06 |
| Change (%) |
-5.00% |
| Day's Open |
1.20 |
| Day's Range |
1.10 - 1.20 |
| Day's Volume |
9,578 |
| 52-Week Range |
1.06 - 3.5 |
More Stats
| Market Cap |
58.20M |
| Enterprise Value |
58.10M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
51.06M |
| Float |
29.12M |
| EPS (basic) |
-0.21 |
| EPS (diluted) |
-0.26 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
1.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
58.79 |
| PB Ratio |
2.31 |
| Revenue |
990,000 |
| Operating Income |
-10.37M |
| Net Income |
-10.08M |
| Free Cash Flow |
-7.53M |
| Net Cash |
107,000 |
| Net Cash / Share |
0.00 |
| Gross Margin |
39.60% |
| Operating Margin |
-1,047.27% |
| Profit Margin |
-1,018.20% |
| FCF Margin |
-760.81% |
| ROA |
-21.51% |
| ROE |
-54.76% |
| ROIC |
-108.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 0.62 | 0.58 | 0.18 | 0.08 | 0.18 |
| Revenue Growth | 6.68% | 223.72% | 114.35% | -54.12% | - |
| Gross Profit | 0.39 | 0.30 | - | -0.07 | 0.07 |
| Operating Income | -13.69 | -7.56 | -7.34 | -3.93 | -1.54 |
| Net Income | -21.36 | -10.40 | -8.15 | -4.16 | -1.60 |
| Shares Outstanding | 34.54 | 25.00 | 23.65 | 9.10 | 6.63 |
| Earnings Per Share | -0.62 | -0.42 | -0.34 | -0.46 | -0.24 |
| Operating Cash Flow | -8.10 | -4.10 | -3.56 | -3.52 | -0.40 |
| Capital Expenditures | -0.41 | -0.06 | -0.10 | -0.12 | -0.19 |
| Free Cash Flow | -8.51 | -4.16 | -3.66 | -3.64 | -0.59 |
| Cash & Equivalents | 4.10 | 0.50 | 0.11 | 1.11 | 0.08 |
| Total Debt | 0.79 | 6.27 | 2.40 | 0.09 | 3.97 |
| Net Cash / Debt | 3.31 | -5.77 | -2.29 | 1.01 | -3.89 |
| Assets | 32.46 | 3.40 | 2.10 | 2.84 | 1.82 |
| Liabilities | 18.95 | 8.55 | 4.09 | 1.12 | 5.66 |
| Book Value | 13.51 | -5.17 | -2.04 | 1.72 | -3.83 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
CURE Pharmaceutical Holding Corp. |
| Country |
United States |
| Employees |
18 |
| CEO |
Robert Steven Davidson |
Stock Information
| Ticker Symbol |
CURR |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
OTCMKTS: CURR |
Description
CURE Pharmaceutical Holding, an integrated drug delivery and development company, focuses on improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. The company is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. It offers CURE 3068 (CUREfilm Sleep), a melatonin-containing sleep aid CUREfilm oral dissolving film (ODF) that is used as a dietary supplement under the brand name ID Life Sleep Strips; and CURE 5079, a sleep aid containing a dietary cannabinoid CUREfilm ODF under the brand name Sleep Stripzzz. The company's products in development stage include CURE 5003 (CUREfilm Blue), a sildenafil CUREfilm ODF, which is in early stage clinical development for the treatment of erectile disorder; CURE 5067 (CUREfilm D), a vitamin D3 CUREfilm ODF for oral administration that is in the optimization development stage; CURE 5200, a CUREfilm ODF substrate; CURE 5209, a CUREfilm ODF for mood enhancement as a dietary supplement; and CURE 5210 (CUREfilm Beta-Caryophyllene), a dietary cannabinoid ODF that is in early feasibility stage to target the CB2 receptor. CURE Pharmaceutical Holding Corp. has a collaboration with Canopy Growth Corporation for the development of low-dose cannabidiol oral thin films. The company was founded in 2011 and is headquartered in Oxnard, California.